Literature DB >> 29212620

One-Year Outcome for Congenital Diaphragmatic Hernia: Results From the French National Register.

François Barrière1, Fabrice Michel2, Anderson D Loundou3, Virginie Fouquet4, Elsa Kermorvant5, Sébastien Blanc6, Elisabeth Carricaburu7, Amélie Desrumaux8, Odile Pidoux9, Alexis Arnaud10, Nicolas Berte11, Thierry Blanc12, Frederic Lavrand13, Guillaume Levard14, Isabelle Rayet15, Sylvain Samperiz16, Anne Schneider17, Marie-Odile Marcoux18, Norbert Winer19, Yann Chaussy20, Valérie Datin-Dorriere21, Quentin Ballouhey22, Aurélien Binet23, Charles Muszynski24, Jean Breaud25, Armelle Garenne26, Laurent Storme27, Julia Boubnova28.   

Abstract

OBJECTIVE: To evaluate the status of congenital diaphragmatic hernia (CDH) management in France and to assess predictors of adverse outcomes. STUDY
DESIGN: We reviewed the first-year outcome of all cases of CDH reported to the French National Register in 2011.
RESULTS: A total of 158 cases were included. Of these, 83% (131) were prenatally diagnosed, with a mortality rate of 39% (44 of 112) for live born infants with a known outcome at hospital discharge. Mortality increased to 47% (60 of 128) including those with termination of pregnancy and fetal loss. This contrasts with the 7% (2 of 27) mortality rate of the patients diagnosed postnatally (P = .002). Mortality worsened with 1 prenatal marker of CDH severity (OR 3.38 [1.30-8.83] P = .013) and worsened further with 2 markers (OR 20.64 [5.29-80.62] P < .001). Classic postnatal risk factors of mortality such as side of hernia (nonleft P = .001), prematurity (P < .001), low birth weight (P = .002), and size of the defect (P < .001) were confirmed. Of the 141 live births (114 prenatal and 27 postnatal diagnosis) with known outcomes, 93 (67%) survived to hospital discharge, 68 (60%) with a prenatal diagnosis and 25 (93%) with a postnatal diagnosis. The median time to hospital discharge was 34 days (IQR, 19.25-62). Of these survivors, 71 (76%) were followed up for 1 year.
CONCLUSIONS: Despite advances in management of CDH, mortality was high and associated with prenatal risk factors. Postnatally, severe persistent pulmonary hypertension was difficult to predict and presented persistent challenges in management.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  congenital diaphragmatic hernia; mortality; outcome; prognosis

Mesh:

Year:  2017        PMID: 29212620     DOI: 10.1016/j.jpeds.2017.09.074

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Early Left Ventricular Dysfunction and Severe Pulmonary Hypertension Predict Adverse Outcomes in "Low-Risk" Congenital Diaphragmatic Hernia.

Authors:  Duy T Dao; Neil Patel; Matthew T Harting; Kevin P Lally; Pamela A Lally; Terry L Buchmiller
Journal:  Pediatr Crit Care Med       Date:  2020-07       Impact factor: 3.624

2.  Longitudinal Analysis of Pulmonary Function in Survivors of Congenital Diaphragmatic Hernia.

Authors:  Duy T Dao; Lystra P Hayden; Terry L Buchmiller; Virginia S Kharasch; Ali Kamran; Charles J Smithers; Samuel E Rice-Townsend; Jill M Zalieckas; Ronald Becker; Donna Morash; Mollie Studley; Jay M Wilson; Catherine A Sheils
Journal:  J Pediatr       Date:  2019-11-06       Impact factor: 4.406

Review 3.  Acutely presenting congenital chest lesions: a primer for the radiologist.

Authors:  Apeksha Chaturvedi; Nina Klionsky; Deepa Biyyam; Mitchell A Chess; Nadia Sultan
Journal:  Emerg Radiol       Date:  2022-03-07

4.  Congenital diaphragmatic hernia presenting with symptoms within the first day of life; outcomes from a non-ECMO centre in Denmark.

Authors:  Ulla Lei Larsen; Søren Jepsen; Thomas Strøm; Niels Qvist; Palle Toft
Journal:  BMC Pediatr       Date:  2020-05-07       Impact factor: 2.125

5.  A systematic review and meta-analysis of surgical morbidity of primary versus patch repaired congenital diaphragmatic hernia patients.

Authors:  Kim Heiwegen; Ivo de Blaauw; Sanne M B I Botden
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.